DaVita Inc. (DVA)
NYSE: DVA · Real-Time Price · USD
117.27
-4.28 (-3.52%)
Nov 17, 2025, 4:00 PM EST - Market closed
DaVita Revenue
DaVita had revenue of $3.42B in the quarter ending September 30, 2025, with 4.80% growth. This brings the company's revenue in the last twelve months to $13.32B, up 5.14% year-over-year. In the year 2024, DaVita had annual revenue of $12.82B with 5.56% growth.
Revenue (ttm)
$13.32B
Revenue Growth
+5.14%
P/S Ratio
0.68
Revenue / Employee
$175,236
Employees
76,000
Market Cap
8.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12.82B | 675.40M | 5.56% |
| Dec 31, 2023 | 12.14B | 530.25M | 4.57% |
| Dec 31, 2022 | 11.61B | -8.90M | -0.08% |
| Dec 31, 2021 | 11.62B | 68.19M | 0.59% |
| Dec 31, 2020 | 11.55B | 162.13M | 1.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DVA News
- 15 hours ago - DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - DaVita Inc. to Participate in Fireside Chat with Wolfe Research - PRNewsWire
- 13 days ago - DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025 - PRNewsWire
- 19 days ago - DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - DaVita misses quarterly profit estimates on rising costs, lower volumes - Reuters
- 19 days ago - DaVita Inc. 3rd Quarter 2025 Results - PRNewsWire
- 4 weeks ago - DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives - PRNewsWire
- 5 weeks ago - DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call - PRNewsWire